Published November 28,2023
Subscribe
Japan on Tuesday introduced its first home COVID-19 vaccine in opposition to the Omicron XBB.1.5 coronavirus subvariant.
A Health Ministry panel stated that the vaccine developed by pharmaceutical agency Daiichi Sankyo is accepted for sensible use, Tokyo-based NHK news company reported.
Experts on the panel stated “they confirmed the vaccine’s effectiveness, and that they have no serious concerns over its safety.”
The vaccine will likely be distributed nationwide in December upon receiving ministry approval.
The ministry accepted Daiichi Sankyo’s plan to provide and promote 1.4 million doses of the XBB.1.5-adapted vaccine, resulting in the acquisition settlement.
Of about 34 million circumstances of COVID-19 since early 2020, Japan suffered about 75,000 deaths, in line with Worldometer figures.
Source: www.anews.com.tr